Shield Therapeutics plc

Equities

STX

GB00BYV81293

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:40:28 2024-05-23 am EDT			5-day change	1st Jan Change
2.4 ^GBX	+17.07%		+29.73%	-64.18%

May. 10	Shield Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 30	EARNINGS AND TRADING: Software Circle & Beximco report higher revenue	AN

Shield Therapeutics plc - Publication of Circular & Notice of General Meeting

December 19, 2022 at 09:05 am EST

Shield Therapeutics plc announces that, further to the announcement on 13 December 2022, confirming the successful completion of the Placing and Subscription, a Circular will shortly be published on the Company's website and will be posted to Shareholders later today.

The Circular contains the notice convening the General Meeting to be held at 2.00 p.m. on 5 January 2023.

Contact:

Tel: +44 (0) 191 511 8500

Email: info@shieldtx.com

Latest news about Shield Therapeutics plc

Shield Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	May. 09	CI
EARNINGS AND TRADING: Software Circle & Beximco report higher revenue	Apr. 30	AN
Transcript : Shield Therapeutics plc, 2023 Earnings Call, Apr 30, 2024	Apr. 30
Transcript : Shield Therapeutics plc, 2023 Sales/ Trading Statement Call, Feb 22, 2024	Feb. 22
FTSE 100 takes hit ahead of FOMC minutes	Feb. 21	AN
Shield Therapeutics sinks as strong performance marred by data issues	Feb. 21	AN
Shield Therapeutics plc Announces Unaudited Sales Results for the Year Ended 31 December 2023	Feb. 21	CI
Shield Therapeutics hires former Akili leader as new CFO	Jan. 09	AN
Shield Therapeutics Names New CFO	Jan. 09	MT
Shield Therapeutics Appoints Santosh Shanbhag as New CFO, Effective January 16, 2024	Jan. 08	CI
Comptoir opens restaurant; Intercede wins contract	Dec. 07	AN
FTSE 100 Ends Higher Fueled by Energy Stocks	23-10-12	DJ
Shield Therapeutics Chief Financial Officer Rudolf to leave	23-10-12	AN
AIM WINNERS & LOSERS: Windward sees high contracting activity levels	23-10-12	AN
Shield Therapeutics CFO to Step Down	23-10-12	MT
Shield Therapeutics plc Announces Hans-Peter Rudolf Is Standing Down from His Role as Chief Financial Officer on 20 October 2023	23-10-12	CI
Aston Martin CEO ups stake; Alkemy's lithium deal	23-10-03	AN
Shield Therapeutics completes USD20 million SWK financing	23-10-03	AN
Shield Therapeutics Closes $20 Million Debt Facility with SWK Funding	23-10-03	MT
EARNINGS AND TRADING: Kingswood cuts outlook; Poolbeg in patent joy	23-10-02	AN
Shield Therapeutics Raises $6 Million via Share Issue	23-09-29	MT
FTSE 100 Closes Thursday Slightly Up as Gilt Yields Weigh on Index	23-09-28	DJ
Shield Therapeutics completes GBP5 million share placing	23-09-28	AN
Shield Therapeutics raises funds for US sales push as loss narrows	23-09-28	AN
Earnings Flash (STX.L) SHIELD THERAPEUTICS Posts H1 Revenue $4.3M	23-09-28	MT

Chart Shield Therapeutics plc

Duration

Period

More charts

Company Profile

Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anaemia. The Company operates through two segments: Feraccru (ferric maltol), and PT20. Its lead product Accrufer/Feraccru is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, United Kingdom, and Switzerland for the treatment of iron deficiency with or without anemia in adults. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.

Sector

Biotechnology & Medical Research

Calendar

2024-06-20 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Shield Therapeutics plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.024 GBP

Average target price

0.16 GBP

Spread / Average Target

+566.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SHIELD THERAPEUTICS PLC	-64.18%	23.86M
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	116B
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B
BIONTECH SE	-6.20%	23.89B
ARGENX SE	-2.33%	21.58B
GENMAB A/S	-6.03%	18.96B
BEIGENE, LTD.	-13.41%	16.33B
WUXI APPTEC CO., LTD.	-40.50%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+6.64%	14.14B
SAREPTA THERAPEUTICS, INC.	+31.84%	12.02B

Bio Therapeutic Drugs